Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
CASSOTIDE 50- BICALUTAMIDE
Bicalutamide - Used for: Treating prostate cancer. Bicalutamide is used in combination with a luteinizing-hormone releasing hormone (LHRH) analog (eg, goserelin, leuprolide). It may also be used for other conditions as determined by your doctor.
Bicalutamide is a nonsteroidal antiandrogen.
Pharmacology: Bicalutamide inhibits the action of androgens.
Indication: Stage D metastatic carcinoma of the prostate in combination with a luteinizing hormone releasing hormone (LHRH) analog.
Bicalutamide is an anti-androgen. It works in the body by preventing the actions of androgens (male hormones).
Bicalutamide is used together with another hormone to treat prostate cancer.
Bicalutamide may also be used for purposes not listed in this medication guide.
Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Oral Palliative treatment of advanced prostatic cancer
Adult: When used with gonadorelin analogue: Usual dose: 50 mg once daily. May be started with or at least 3 days before starting gonadorelin analogue therapy. Oral Monotherapy or adjuvant therapy to surgery or radiotherapy in locally advanced prostatic cancer
Adult: 150 mg once daily.
Adult: PO Palliation of advanced prostate cancer Usual: 50 mg once daily, may start w/ or at least 3 days before starting gonadorelin analogue therapy. Monotherapy or adjuvant therapy to surgery or radiotherapy in locally advanced prostatic cancer 150 mg once daily.